Leucine, a New York-based digitalized pharmaceutical manufacturing company, raised $7M in Series A funding.
The round was led by Ecolab, with participation from all existing investors, including Pravega Ventures, Axilor Ventures, Techstars, and angels.
The company intends to use the funds to refine its AI capabilities to make its AI Co-pilot a partner to production and quality managers on the shop floor, and expand its reach to more facilities and customers.
Led by Vivek Gera, Founder and CEO, and Mustaq Singh Bijral, Co-founder and CPO, Leucine is at the forefront of digitizing pharmaceutical manufacturing, leveraging AI technologies to bring efficiency and compliance to the shop floor.
Its solutions, from Batch Planning to Batch Release, aim to optimize traditional procedures, replacing paper-based records with a digital-first approach. Used by industry leaders, Leucine streamlines the manufacturing process and delivers actionable insights through its AI-driven analytics dashboard, empowering pharma companies to produce safer and more effective medicines.
The company is today also announcing the beta launch of Leucine10x, an AI framework designed to serve as a co-pilot in pharmaceutical manufacturing processes. Built on proprietary LLM technology, Leucine10x’ AI co-pilots perform specialized tasks such as digitizing paper-based SOPs, creating a digital twin of the shop floor, collaborating with Production Managers in creating dynamic production plans, thus ensuring on-time batch delivery.
The company is currently deployed at over 30 companies in over 300 pharma manufacturing facilities across 10 countries, including the US, India, Brazil, Mexico, UAE, and others.
FinSMEs
16/10/2023